TELADOC HEALTH INC (TDOC)
US87918A1051 - Common Stock
Overall TDOC gets a fundamental rating of 4 out of 10. We evaluated TDOC against 40 industry peers in the Health Care Technology industry. The financial health of TDOC is average, but there are quite some concerns on its profitability. While showing a medium growth rate, TDOC is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year TDOC has reported negative net income.
TDOC had a positive operating cash flow in the past year.
In the past 5 years TDOC always reported negative net income.
TDOC had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
TDOC has a better Return On Assets (-5.02%) than 76.92% of its industry peers.
The Return On Equity of TDOC (-9.47%) is better than 76.92% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -5.02% | ||
| ROE | -9.47% | ||
| ROIC | N/A |
ROA(3y)-107.27%
ROA(5y)-66.14%
ROE(3y)-201.33%
ROE(5y)-123.36%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Gross Margin, with a value of 70.80%, TDOC is in the better half of the industry, outperforming 66.67% of the companies in the same industry.
TDOC's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for TDOC so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 70.8% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.28%
GM growth 5Y0.46%
2. Health
2.1 Basic Checks
TDOC does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, TDOC has more shares outstanding
Compared to 5 years ago, TDOC has more shares outstanding
The debt/assets ratio for TDOC has been reduced compared to a year ago.
2.2 Solvency
TDOC has an Altman-Z score of -3.47. This is a bad value and indicates that TDOC is not financially healthy and even has some risk of bankruptcy.
TDOC has a worse Altman-Z score (-3.47) than 64.10% of its industry peers.
TDOC has a debt to FCF ratio of 7.94. This is a slightly negative value and a sign of low solvency as TDOC would need 7.94 years to pay back of all of its debts.
TDOC's Debt to FCF ratio of 7.94 is fine compared to the rest of the industry. TDOC outperforms 74.36% of its industry peers.
TDOC has a Debt/Equity ratio of 0.66. This is a neutral value indicating TDOC is somewhat dependend on debt financing.
TDOC has a Debt to Equity ratio of 0.66. This is in the lower half of the industry: TDOC underperforms 69.23% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.66 | ||
| Debt/FCF | 7.94 | ||
| Altman-Z | -3.47 |
ROIC/WACCN/A
WACC8.1%
2.3 Liquidity
TDOC has a Current Ratio of 3.54. This indicates that TDOC is financially healthy and has no problem in meeting its short term obligations.
TDOC has a Current ratio of 3.54. This is in the better half of the industry: TDOC outperforms 66.67% of its industry peers.
A Quick Ratio of 3.47 indicates that TDOC has no problem at all paying its short term obligations.
TDOC's Quick ratio of 3.47 is fine compared to the rest of the industry. TDOC outperforms 69.23% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.54 | ||
| Quick Ratio | 3.47 |
3. Growth
3.1 Past
TDOC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 96.93%, which is quite impressive.
The Revenue has grown by 8.12% in the past year. This is quite good.
The Revenue has been growing by 44.17% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)96.93%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q99.28%
Revenue 1Y (TTM)8.12%
Revenue growth 3Y33.49%
Revenue growth 5Y44.17%
Revenue growth Q2Q3.58%
3.2 Future
TDOC is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 20.15% yearly.
TDOC is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 6.66% yearly.
EPS Next Y21.39%
EPS Next 2Y21%
EPS Next 3Y19.7%
EPS Next 5Y20.15%
Revenue Next Year2.06%
Revenue Next 2Y2.85%
Revenue Next 3Y3.07%
Revenue Next 5Y6.66%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for TDOC. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TDOC. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
82.05% of the companies in the same industry are more expensive than TDOC, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, TDOC is valued cheaply inside the industry as 94.87% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 11.37 | ||
| EV/EBITDA | 20.69 |
4.3 Compensation for Growth
A more expensive valuation may be justified as TDOC's earnings are expected to grow with 19.70% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y21%
EPS Next 3Y19.7%
5. Dividend
5.1 Amount
No dividends for TDOC!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TELADOC HEALTH INC
NYSE:TDOC (4/26/2024, 7:19:01 PM)
After market: 13.0499 +0.04 (+0.31%)13.01
-0.32 (-2.4%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap2.20B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -5.02% | ||
| ROE | -9.47% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 70.8% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.59
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.66 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 3.54 | ||
| Quick Ratio | 3.47 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)96.93%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y21.39%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)8.12%
Revenue growth 3Y33.49%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y